🔗 Share this article

As the US continues making historic changes to its vaccine recommendations, a particular individual has surfaced somewhat surprisingly: Tracy Beth Høeg, a US-based physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots in the global health crisis and has focused upon potential fatalities after COVID-19 vaccination in her brief tenure at the Food and Drug Administration.

Planned Shifts to Childhood Vaccine Schedule

Public health authorities were set to announce sweeping revisions to the childhood vaccination calendar in December, aligning the US with the Danish immunization schedule, it is understood – a significant shift that would put the US out of step with many the global community with little proof for public health gain. The announcement has been delayed until the new year.

Rather than the director of the vaccine center, Dr. Høeg is set to speak at the meeting. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the center this year.

Consolidating Power at the FDA

Høeg's temporary position might represent a tighter collaboration between the drug and vaccine centers as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

The new acting director has frequently advocated for ending specific childhood immunization guidelines in the US so as to align more like Denmark, a nation with universal health coverage and a population roughly the size of the state of Wisconsin.

To date public appearances, she has kept her attention on immunizations – typically the responsibility of Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Questions Over Qualifications

The appointee has no apparent background in pharmaceutical research, regulation or leadership, which has been standard for previous heads of the CBER. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for running the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in leading a major agency. She has no expertise in drug approvals.”

Previous directors of CBER would “grasp legal statutes and the research of pharmaceutical innovation”, said Janet Woodcock. “Frankly, she doesn’t have the kind of background that former directors who ran CBER have had.”

This division has an enormous workload at the agency, the former commissioner emphasized.

“The public just pays attention on the innovative therapies, but the off-patent medication office authorizes a multitude of generic medications. There’s a biosimilars division, OTC medication office and so forth, and all of those need to be supervised,” Dr. Woodcock said. “The thing you neglect, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial leadership component to the job, which oversees in excess of 5,000 personnel. “It’s a huge leadership role, if you execute it properly,” she added.

Official Statement and Contentious Policies

In response to questions about Høeg’s credentials and whether this assignment represents increased cooperation among agency officials on immunizations, a press secretary said that the “concerns stem from incorrect premises”.

“Her resume matches the functions of her job,” the representative stated, citing the months Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

As acting director, Høeg inherits the agency head's controversial priority voucher program, a disputed expedited therapy clearance system that apparently concerned her former heads. “How are these drugs being chosen for this voucher program? Who makes the choices?” Howard asked. “There’s a lot of lack of transparency occurring at the FDA right now.”

Overall, he remarked, “the agency appears to be shifting towards less stringent rules of most medications, aside from immunizations.”

Documented Past Work on Vaccines

Regarding vaccines, Høeg has a clearer, if problematic, history, critics said. She released a study using unconfirmed public submissions to determine the frequency of heart inflammation following Covid vaccination. She counseled the Florida surgeon general Joseph Ladapo, who allegedly have altered data to imply COVID-19 vaccinations are riskier than they are.

Included in her “policy goals” for the new government encompassed changing guidelines for novel immunizations and discontinuing “unnecessary” immunizations, she stated following the vote on a audio program. At the agency, Høeg has according to sources proposed barring young men from receiving COVID-19 vaccines.

“She is an thorough ideologue who begins with her beliefs and reverse-engineers to fit the science in a very disingenuous, fraudulent fashion,” Howard argued.

Gaining Influence and a “Push for Payback”

Dr. Høeg aligned with other dissenters, {like|